Luke J. Laffin at LBS briefing 1

Luke J. Laffin, M.D., preventive cardiologist at the Cleveland Clinic presents findings of the First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 (LBS.01) at the embargoed media briefing at Scientific Sessions 2025.

Please see AHA/ASA Multimedia Materials Usage Policy.

I have read the AHA/ASA Multimedia Materials Usage Policy and agree to the terms of use

Download (457.4 kB)

This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.

CLOSE PROCEED